902-903 / 2437
Summary for Anaplastic Astrocytoma
•
Upfront chemotherapy with PCV resulted in improved survival
in patients treated for oligodendroglioma and oligoastrocytoma,
with 1p/19q co-deletion
1,2
•
Interim results from EORTC 26053-22054 demonstrated a
signigicant survival benefit in patients with non co-deleted
anaplastic astrocytoma adding adjuvant TMZ to RT
3
•
The question of concomitant RT/TMZ remains open until the
final analysis of the CATNON trial
•
Repeated surgery and Re-irradiation is still an option for
recurrent disease in combination with systemic therapy (CHT
and BEV)
1.
Van den Bent, et al. JCO, 2013
2.
Cairncross, et al. JCO, 2014
3.
Van den Bent, et al. The Lancet, 2017